Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | CA3 | P07451 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | CA9 | Q16790 | 1/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 6/20 | 0.65 |
| ▸ | MAOB | P27338 | 6/20 | 0.65 |
| ▸ | MMP3 | P08254 | 1/20 | 0.64 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394075 | 0.88 | MAOB (0.81) | CA12CA2CA3CA6CA9 | |
| 4-Cyanophenol SCHEMBL28811803 | 0.85 | CA2 (1.00) | CA12CA2CA3CA6CA9 | |
| 4-Cyanophenol SCHEMBL27294505 | 0.85 | CA2 (1.00) | CA12CA2CA3CA6CA9 | |
| 4-Cyanophenol SCHEMBL50814 | 0.85 | — | — | |
| Cyanate SCHEMBL9244238 | 0.83 | NR1H2 (0.74) | CA12CA2CA3CA6CA9 | |
| 4-Cyanophenol SCHEMBL27413520 | 0.83 | CA2 (0.94) | CA12CA2CA3CA6CA9 | |
| 4-Cyanophenol SCHEMBL28089570 | 0.83 | CA2 (0.94) | CA12CA2CA3CA6CA9 | |
| 4-Cyanophenol SCHEMBL7393582 | 0.83 | CA2 (0.94) | CA12CA2CA3CA6CA9 | |
| 4-Cyanophenol SCHEMBL10685886 | 0.83 | CA2 (0.94) | CA12CA2CA3CA6CA9 | |
| SCHEMBL7289176 | 0.81 | MAOA (0.53) | CA12CA2CA3CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3553129-B1 | CURING RESIN COMPOSITION, CURED PRODUCT OF, AND CURING METHOD FOR, CURING RESIN COMPOSITION, AND SEMICONDUCTOR DEVICE | ENEOS CORP (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-20210070779-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070779-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200207789-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS INC (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207789-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS INC (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3553129-A1 | CURING RESIN COMPOSITION, CURED PRODUCT OF, AND CURING METHOD FOR, CURING RESIN COMPOSITION, AND SEMICONDUCTOR DEVICE | JXTG Nippon Oil & Energy Corporation (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-20180291040-A1 | Boron-Containing Small Molecules As Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS INC (US) | 2018-10-11 | — | — | US | disclosed |
| US-20160200743-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160200743-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2015042532-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015042532-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-6242654-B1 | REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1013629-A1 | Preparation process of fluorine subsituted aromatic compound | Mitsui Chemicals, Inc. (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200743-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, TNF | CA12 1548/4885CA2 1112/4885CA3 3542/4885 |
| US-20210070779-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, TNF, LITAF | CA12 1428/4885CA2 964/4885CA3 3626/4885 |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | NR3C1, NR3C2, MC2R | CA12 4577/4885CA2 3320/4885CA3 4695/4885 |
| US-20200207789-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, TNF, LITAF | CA12 1428/4885CA2 964/4885CA3 3626/4885 |
| US-20180291040-A1 | Boron-Containing Small Molecules As Anti-Inflammatory Agents | NFKBIA, TNF, LITAF | CA12 1428/4885CA2 964/4885CA3 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.